

ESMO Preceptorship Programme Gastric Cancer

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

10-11 June 2016, Prague, Czech Republic

Co-Chairs:

Andrés Cervantes, Spain
Jean-Yves Douillard, France

Speakers:

William Allum, United Kingdom
Fatima Carneiro, Portugal
Karin Haustermans, Belgium

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, etiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

Friday 10th June 2016

09:00-9:10	Opening and Welcome	
5'	Welcome from ESMO	Andrés Cervantes, ES Jean-Yves Douillard, FR
5'	Objectives of the meeting	Jean-Yves Douillard, FR
09:10-10:55 105'	Module 1 Epidemiology, pathology and endoscopy of gastric cancer	
30'	Epidemiology (including GE junction tumours) and clinical presentation	Andrés Cervantes, ES
30'	Pathology and carcinogenesis	Fatima Carneiro, PT
30	Endoscopy in gastric cancer: new imaging techniques, new treatment modalities (EMR, ESD)	TBC
15'	discussion	
10:55-11:30	Coffee Break	

11:30-13:00 90'	Module 2 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	
30'	Surgery for gastric and GE junction cancer, primary, palliative - where and when?	William Allum, UK
25'	Neo- and adjuvant treatment for gastric cancer and GE junction cancer: The role of radiotherapy	Karin Haustermans, BE
25'	Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy	TBC
10'	Discussion	

13:00-14:00	Lunch
-------------	-------

14:00-15:10 70'	Module 3 Clinical discussions	
60'	Molecular events and classification in gastric cancer Hereditary gastric cancer	Fatima Carneiro, PT
10'	Discussion	

15:10 – 15:30	Coffee Break
---------------	--------------

15:30-17:30 120'	Module 4 Advanced disease	
30'	Chemotherapy for metastatic disease	TBC
40'	Biological targeted agents (including HER2, EGFR, angiogenesis,)	Jean-Yves Douillard, FR
40'	New targets (including cMET, FGF, mTOR, PDL...)	Andrés Cervantes, ES
10'	Discussion	

19:30-22:30	Dinner
-------------	--------

Saturday 11th June 2016

09:00-10:10 70'	Module 5 Practical case discussion	
70'	Case discussion based on ESMO recommendations/guidelines	Jean-Yves Douillard, FR Andrés Cervantes, ES

10:10 – 10:40	Coffee break
---------------	--------------

10:40-12:00 80'	Module 6 Case discussions and questions	
4x20'	4 x Participants' clinical cases discussion	Jean-Yves Douillard, FR Andrés Cervantes, ES Karin Haustermans, BE William Allum, UK

Each 20 min slot for clinical cases discussion includes 10' case presentation and 10' Q&A / panel discussion

12:00-12:30 30'	Module 7 Future outlook	
20'	What we have learned from recent clinical studies and where do we go from here? Future outlook	TBC
10'	Closing remarks and take-home messages	Jean-Yves Douillard, FR Andrés Cervantes, ES

12:30-13:30	Lunch
-------------	-------